Workflow
广生堂(300436) - 2018 Q3 - 季度财报
CosunterCosunter(SZ:300436)2018-10-25 16:00

Financial Performance - Operating revenue for the reporting period was CNY 123,346,675.39, a 70.02% increase year-on-year, while year-to-date revenue reached CNY 285,616,279.74, up 28.23%[8] - Net profit attributable to shareholders decreased by 79.50% to CNY 1,706,013.25 for the reporting period[8] - The company's basic earnings per share were CNY 0.0121, a decrease of 20.92% year-on-year[8] - The company reported a significant increase in fixed assets from CNY 109,856,000.26 to CNY 187,418,088.37, representing a growth of about 70.6%[29] - The company reported a total profit of ¥2,018,288.43, down from ¥3,386,857.15, a decrease of approximately 40%[36] - The company's net profit for Q3 2018 was CNY 6,118,521.57, a significant decrease of 79.24% compared to CNY 29,427,791.37 in the same period last year[41] - The total profit for the period was CNY 6,746,379.96, down 80.3% from CNY 34,141,945.97 in the previous year[41] Cash Flow - The company reported a net cash flow from operating activities of CNY -11,024,515.63, a decline of 118.66%[8] - The net cash flow from operating activities was -10,941,693.09 CNY, a significant decrease compared to 63,147,610.62 CNY in the previous period, indicating a decline of approximately 117% in cash generation from operations[51] - The total cash inflow from operating activities was 289,896,297.12 CNY, slightly down from 297,787,486.89 CNY, a decrease of approximately 3%[51] - The company reported a negative cash flow from operating activities of CNY -11,024,515.63, contrasting with a positive cash flow of CNY 59,074,892.81 in the same period last year[48] - The total cash outflow from investing activities was CNY 271,224,627.94, compared to CNY 558,072,103.93 in the previous year[48] - The net cash flow from investment activities was -280,547,406.43 CNY, worsening from -153,365,591.90 CNY in the prior period, indicating an increase in cash outflow of approximately 83%[51] Assets and Liabilities - Total assets increased by 13.44% to CNY 835,438,174.37 compared to the end of the previous year[8] - Current assets decreased significantly from CNY 472,852,330.77 to CNY 199,667,776.06, a decline of about 57.8%[30] - Total liabilities rose to CNY 280,923,513.09 from CNY 184,421,266.64, an increase of approximately 52.3%[30] - The company’s net assets attributable to shareholders decreased by 1.04% to CNY 546,282,046.91 compared to the end of the previous year[8] - Accounts receivable rose to CNY 67,341,065.73 from CNY 32,743,479.77, marking an increase of approximately 105.5%[28] - Inventory increased from CNY 24,285,487.00 to CNY 33,038,119.16, reflecting a growth of about 36.0%[28] Research and Development - Research and development expenses totaled CNY 87 million, an increase of CNY 32.21 million year-on-year, with CNY 52.16 million classified as expensed R&D[16] - The company has made significant progress with the innovative drug GST-HG141, which has entered the IND development stage, showing promise for functional cure of hepatitis B[20] - The clinical trial application for the innovative drug GST-HG161 targeting liver cancer has been accepted by the National Medical Products Administration, marking a significant transition from a generic drug company to an innovative drug company[19] - Research and development expenses were ¥13,909,748.13, down from ¥17,299,051.96, showing a reduction of about 20%[35] Subsidiaries and Acquisitions - The company’s subsidiary, Jiangsu Zhongxing Pharmaceutical Co., contributed CNY 36.61 million to the operating revenue during the reporting period[16] - The company completed the fundraising project from its initial public offering and will permanently supplement its working capital with the remaining funds[20] - The company's goodwill increased to CNY 58.53 million as a result of the acquisition of subsidiary Jiangsu Zhongxing[18] - The company has received approval from the China Securities Regulatory Commission for a non-public stock issuance, aiming to raise up to CNY 1 billion for international pharmaceutical base construction and a high-end medical hospital project[19] Operating Costs - Total operating costs amounted to ¥121,514,235.61, compared to ¥72,186,939.87 in the prior period, reflecting an increase of about 68%[35] - Total operating costs for the consolidated entity were ¥277,335,245.37, compared to ¥189,857,944.49, an increase of about 46%[39] - Sales expenses increased by CNY 52.99 million, driven by a shift to direct sales, with direct sales revenue proportion rising from 60% to 79%[16]